New viral vaccines, based on molecular research into genomes and proteins, should come into routine use in the coming decades. At the same time, use of different immunizing antigens within a single dose is also expected to grow more common, with the purpose of reducing the number of vaccinations administered to target populations. Given Brazil's scientific and technological importance, the country should enhance its participation in the development of new vaccines and in the evaluation of their efficacy by involving a larger number of researchers and technologists and boosting investment in these activities.
viral vaccines; immunizing antigens; Brazil